Genedx Earnings Call Resets Outlook Amid Strong Growth

Genedx Holdings Corp. ((WGS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Genedx Holdings Corp. struck a cautious but constructive tone on its latest earnings call. Management highlighted robust test growth, resilient margins and a powerful data moat, yet paired that with frank discussion of revenue misses, mix headwinds and a sizable impairment that forced a reset to guidance and a more disciplined execution plan.

Robust Volume Growth

Test result volume climbed 34% year over year in Q1 to 27,488, underscoring strong demand for the company’s genetic testing services. Growth was broad-based across both core and expansion markets, suggesting underlying clinical adoption remains intact despite reimbursement friction.

Exome & Genome Revenue Momentum

Exome and genome revenue reached $90.6 million, up 27% from a year ago and now representing the clear engine of the business. The figures show GeneDx is successfully shifting physicians toward higher-content sequencing even as it navigates a more challenging payor and product-mix environment.

Large and Differentiated Data Asset

The company emphasized its proprietary database of more than 2.5 million contactable patients and over 1 million exomes and genomes. With more than 8 million matched phenotypic profiles, management cast this asset as a key moat for faster interpretation, payer negotiations and long-term biopharma collaborations.

Healthy Margins and Profit Path

Adjusted gross margin came in at 69% for Q1, reinforcing the scalability of the sequencing platform even with mix pressure. Management reiterated a target of roughly 70% adjusted gross margin by 2026 and a return to adjusted profitability by year-end, with further profit expansion eyed into 2027.

Commercial & Product Initiatives

GeneDx rolled out a Reflex offering in February to balance genome adoption with unit economics and mitigate reimbursement risk. It also expanded commercial coverage with about 75 specialist reps, 50 in general pediatrics and dedicated NICU and prenatal teams, and noted early traction in NICU and encouraging initial orders from pediatricians.

Updated Guidance and Line-of-Sight Execution

The company reset its 2026 outlook to $475 million to $490 million in revenue, down from prior expectations but built on clearer visibility. Management now frames the plan around at least 30% exome and genome volume growth and 20% revenue growth, coupled with tight cost control and a focus on markets where demand and reimbursement are most predictable.

Cost Discipline and Focused Investment

To align spending with the revised forecast, GeneDx is cutting and recalibrating about $25 million of operating expenses for 2026. Investment will be concentrated on three levers: boosting test utilization, improving average reimbursement and cost of goods, and scaling a focused portfolio of leading genomic products.

Q1 Revenue Shortfall vs. Expectations

Total Q1 revenue of $102.3 million landed roughly $12 million below internal expectations, forcing a guidance reset. Management pointed to shortfalls in both core reimbursement and non-core units as the main culprits, even as overall demand trends and test growth remained strong.

Blended ARR and Mix Pressure

Blended average reimbursement rate was about $3,300, around $200 shy of targets due to mix and coverage issues. Outpatient exome tests earned about $4,000 on average, while outpatient genome reimbursements were roughly half that, further weighed by a lower share of higher-paying parental comparator samples.

Non-Core Underperformance and Fabric Impairment

Non-core lines including Fabric, biopharma and multi-gene panels collectively missed by about $6.5 million in Q1. Fabric’s shortfall triggered a roughly $31.3 million non-cash impairment and a narrowed role in future plans, with the business now refocused on select international opportunities rather than broad-based growth.

Profitability Impact and Guidance Reduction

GeneDx reported an adjusted net loss of $8.2 million in Q1 and trimmed full-year revenue expectations by about 12%, a $65 million cut at the midpoint. The downgrade stems largely from lower blended reimbursement, softer expansion-market volume and lower non-core contributions, even as management keeps its long-term profitability goals intact.

Revenue Cycle and Payer Coverage Constraints

Management acknowledged that genome reimbursement remains constrained by less mature payer coverage and higher costs, creating ongoing denial and collection complexity. They cautioned that meaningfully lifting genome reimbursement will likely take several quarters as coverage policies evolve and revenue cycle processes are refined.

Forecasting and Mix Execution Issues

The company admitted it misjudged late-quarter shifts in test mix, particularly the uptake of genome and fewer trio samples, which weighed on realized pricing. In response, executives are tightening forecasting by reviewing each channel and adjusting sales incentives, mix assumptions and operational plans to better track demand patterns.

Reset Guidance and Forward Outlook

Looking ahead, GeneDx now guides 2026 revenue to $475 million to $490 million, underpinned by at least 30% volume growth and about 70% adjusted gross margin with a goal of adjusted profitability for the year. For Q2, management expects $110 million to $112 million in revenue and a smaller adjusted net loss, with a planned shift into adjusted profitability as soon as the third quarter.

Genedx’s latest call painted a company with strong clinical momentum but a need for sharper execution and more realistic expectations. For investors, the story now hinges on whether management can translate robust test growth and a unique data advantage into sustained reimbursement gains, cleaner forecasting and the promised return to profitability by 2026.